Envarsus
Total Payments
$5.1M
Transactions
4,591
Doctors
1,370
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $1.2M | 1,558 | 715 |
| 2021 | $1.0M | 814 | 359 |
| 2020 | $1.5M | 922 | 293 |
| 2019 | $1.3M | 1,297 | 481 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.2M | 94 | 63.6% |
| Consulting Fee | $991,075 | 382 | 19.5% |
| Travel and Lodging | $435,391 | 584 | 8.6% |
| Food and Beverage | $217,593 | 3,124 | 4.3% |
| Honoraria | $117,403 | 71 | 2.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $62,178 | 129 | 1.2% |
| Education | $26,375 | 207 | 0.5% |
Payments by Type
Research
$3.2M
94 transactions
General
$1.9M
4,497 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus | Veloxis Pharmaceuticals, Inc. | $251,336 | 0 |
| Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant | Veloxis Pharmaceuticals, Inc. | $191,849 | 0 |
| A Prospective Randomized Multicenter OpenLabel Pilot Study to Investigate Medication Adherence and Patient Reported Symptom Occurrence and Interference with Daily Life Comparing OnceDaily Envarsus XR and TwiceDaily Immediate Release Tacrolimus in Adult Renal Transplant Recipients | Veloxis Pharmaceuticals, Inc. | $183,600 | 0 |
| A Prospective, Randomized, Multicenter, Open-Label, Pilot Study to Investigate Medication Adherence and Patient Reported Symptom Occurrence and Interference with Daily Life Comparing Once-Daily Envarsus XR and Twice-Daily Immediate Release Tacrolimus in Adult Renal Transplant Recipients | Veloxis Pharmaceuticals, Inc. | $183,600 | 0 |
| Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection | Veloxis Pharmaceuticals, Inc. | $151,070 | 0 |
| Envarsus Neurotoxicity Burden in Liver Transplant Patients | Veloxis Pharmaceuticals, Inc. | $146,786 | 0 |
| A Phase IV, Prospective, Randomized, Open-label, Single-Center Study of Pulse Wave Velocity Evaluation, Tacrolimus Time in Therapeutic Range and Co-Efficient fo Tacrolimus Variation of African American Kidney Transplant Recipients Receiving Immediate Release Tacrolimus Capsules (IR-Tac) or Extended Release | Veloxis Pharmaceuticals, Inc. | $133,229 | 0 |
| Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants (PTAAK) | Veloxis Pharmaceuticals, Inc. | $122,354 | 0 |
| Prospective Pilot Feasibility Study Comparing Envarsus Onceaday to Tacrolimus Twiceaday Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients | Veloxis Pharmaceuticals, Inc. | $119,933 | 0 |
| Early Use of Longacting Tacrolimus in Lung Transplant Recipients | Veloxis Pharmaceuticals, Inc. | $102,729 | 0 |
| A 12 Month Singlecenter Open Label Randomized Comparative Study to Evaluate Envarsus XL Steroidfree Rabbit Antithymocyte Globulin Induction on Renal Function and Healthrelated Quality of Life Following Liver Transplantation | Veloxis Pharmaceuticals, Inc. | $84,420 | 0 |
| Veloxis de Novo Kidney Transplant ECSWD | Veloxis Pharmaceuticals, Inc. | $82,096 | 0 |
| Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus EVOKE RT | Veloxis Pharmaceuticals, Inc. | $80,978 | 0 |
| Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (SIMPLE) | Veloxis Pharmaceuticals, Inc. | $75,292 | 0 |
| Impact of Envarsus XR (r) on kidney biopsy subclinical rejection and blood immunologic profile | Veloxis Pharmaceuticals, Inc. | $71,464 | 0 |
| Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in HLA Sensitized Kidney Transplant Recipients | Veloxis Pharmaceuticals, Inc. | $70,665 | 0 |
| An observational study to determine if early tacrolimus troughs detect repid trcrolimus metabolizers | Veloxis Pharmaceuticals, Inc. | $69,532 | 0 |
| Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients | Veloxis Pharmaceuticals, Inc. | $66,395 | 0 |
| An Evaluation of Converting Elderly Kidney Transplant Recipients from Tacrolimus to Envarsus to Limit Neurological Adverse Events and Improve Quality of Life | Veloxis Pharmaceuticals, Inc. | $65,625 | 0 |
| Envarsus XR in Lung Transplant | Veloxis Pharmaceuticals, Inc. | $64,440 | 0 |
Top Doctors Receiving Payments for Envarsus — Page 55
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Transplant Surgery | Birmingham, AL | $12.00 | 2 |
| Shikha Mehta | Nephrology | Birmingham, AL | $12.00 | 2 |
| , M.D., PH.D | Surgery | New Brunswick, NJ | $12.00 | 2 |
| , MD | Nephrology | Falls Church, VA | $12.00 | 1 |
| , MBBS | Internal Medicine | Pittsburgh, PA | $12.00 | 2 |
| , MD | Transplant Surgery | Falls Church, VA | $12.00 | 1 |
| Babak Orandi | Surgery | Birmingham, AL | $12.00 | 2 |
| Bandar Aljudaibi | Gastroenterology | Rochester, NY | $12.00 | 2 |
| Jayme Locke | Surgery | Birmingham, AL | $12.00 | 2 |
| , MD | Nephrology | Sioux Falls, SD | $11.77 | 1 |
| , M.D | Nephrology | Las Vegas, NV | $11.36 | 1 |
| , MD, PHD | Transplant Surgery | Columbus, OH | $11.00 | 2 |
| , MD | Nephrology | Jackson, MS | $10.95 | 1 |
| , M.D | Transplant Surgery | New York, NY | $10.82 | 1 |
| , MD | Cardiovascular Disease | London, KY | $10.82 | 1 |
| , MD | Transplant Surgery | New York, NY | $6.00 | 1 |
| , MD | Surgery | New Orleans, LA | $6.00 | 1 |
| , M.D | Gastroenterology | Burlington, MA | $5.90 | 1 |
| , M.D | Transplant Surgery | Sacramento, CA | $5.00 | 1 |
| , M.D | Nephrology | New Orleans, LA | $5.00 | 1 |
| Chaplin Liu | — | San Leadnro, CA | $5.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.1M
- Total Doctors 1,370
- Transactions 4,591
About Envarsus
Envarsus is a drug associated with $5.1M in payments to 1,370 healthcare providers, recorded across 4,591 transactions in the CMS Open Payments database. The primary manufacturer is Veloxis Pharmaceuticals, Inc..
Payment data is available from 2019 to 2022. In 2022, $1.2M was paid across 1,558 transactions to 715 doctors.
The most common payment nature for Envarsus is "Unspecified" ($3.2M, 63.6% of total).
Envarsus is associated with 20 research studies, including "Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus" ($251,336).